Sequence information


DRAVP ID  DRAVPc036

Name   Gimsilumab(MORAB-022)

Sequence 

Molecular Formula  Not Available

Condition/Disease  COVID-19

Group  Phase â…ˇclinical trial

Type  Antibody

Description  Gimsilumab is under investigation in clinical trial and used for COVID-19.

Active sequence/Structure 


External Links


DrugBank Accession Number  DB15280

Pubchem ID  381127889

CHEMBL ID  CHEMBL2109430

UNII  8961SFA7R3

CAS  1648796-29-5

Reference  Not Available



ClinicalTrails Information


NCT Number Study Title Condition/Disease Status Phase Sponsor
NCT04351243 A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE) Coronavirus Disease 2019 (COVID‑19) Treatment Completed Phase 2 Kinevant Sciences GmbH